ADMINISTERING COMPOSITIONS FOR IMPROVED IMMUNE SYSTEM FUNCTIONING

Abstract

The present disclosure relates to methods of administering a composition to a patient, particularly in the form of a dietary supplement, which addresses immune system deficiencies and promotes healthy immune system functioning. The present disclosure also related to compositions and methods for improving or boosting immune system functioning. The present disclosure further provides novel compositions for balancing immune response in human subjects.

Claims

1. A method of treating a patient with an immune system deficiency, comprising: administering to the patient with a capsule, wherein the capsule comprises: from about 250 to 750 mcg of EpiCor Yeast Fermentate; from about 100 to 300 mg the Olive Leaf 20% Extract; and from about 100 to 300 mg of Andrographis Extract; from about 100 to 300 mg N-acetylcysteine; from about 50 to 150 mg Skullcap Root Extract; and from about 12.5 to 200 mg Trans-Resveratrol.

2. The method of claim 1, wherein the immune system deficiency is Hashimoto's disease.

3. The method of claim 1, wherein the composition is administered to the patient in the form of a dietary supplement.

4. The method of claim 1, wherein the composition is administered to the patient in the form of an acid resistant capsule.

5. The method of claim 1, wherein the composition is administered orally in the form of a tablet.

6. The method of claim 1, wherein the composition administered to the patient further comprises a palatability agent.

7. The method of claim 6, wherein the palatability agent is at least one of a plant oil, plant hydrolysates, yeast, and yeast hydrolysates, and combinations thereof.

8. The method of claim 1, wherein the composition administered to the patient does not include milk, casein, gluten, wheat, eggs, peanuts, tree nuts, dairy, corn, soybeans, sugar and fish/shellfish.

9. The method of claim 1, wherein the Trans-resveratrol is provided in the form of polygonum cuspidatum.

10. A method of improving immune system functioning in a patient exhibiting disorders relating to the same, wherein the method comprises administering a composition consisting essentially of: 500 mg of Dried Yeast Fermentate; 200 mcg of Olive Leaf Extract; 200 mg of Andrographis Extract; 200 mg of N-acetylcysteine; 100 mg of Skullcap Root Extract; and 25 mg of Trans-Resveratrol.

11. The method of claim 10, wherein the Trans-Resveratrol is selected from 50 mg polygonum cuspidatum.

12. The method of claim 10, wherein the composition administered to the patient is devoid of the following: milk, casein, gluten, wheat, eggs, peanuts, tree nuts, dairy, corn, soybeans, sugar and fish/shellfish.

13. The method of claim 10, wherein the composition is administered to the patient in the form of a dietary supplement.

14. The method of claim 10, wherein the composition is administered to the patient in the form of an acid resistant capsule.

15. The method of claim 10, wherein the composition is administered orally in the form of a tablet.

16. The method of claim 10, wherein the composition further comprises at least one palatability agent.

17. The method of claim 16, wherein the palatability agent is at least one of a plant oil, plant hydrolysates, yeast, and yeast hydrolysates, and combinations thereof.

Description

DETAILED DESCRIPTION

[0033] Although the following text sets forth a Detailed Description of numerous different embodiments, it should be understood that the legal scope of the description is defined by the words of the claims set forth at the end of this disclosure. The Detailed Description is to be construed as exemplary only, and does not describe every possible embodiment since describing every possible embodiment would be impractical, if not impossible. Numerous alternative embodiments could be implemented, using either current technology or technology developed after the filing date of this patent, which would be encompassed by the scope of the claims.

[0034] As used herein, references to “the present invention” or aspects thereof should be understood to mean certain embodiments of the present invention and should not necessarily be construed as limiting all embodiments to a particular description.

[0035] As used herein, the phrases “at least one”, “one or more”, and “and/or” are open-ended expressions that are both conjunctive and disjunctive in operation. For example, each of the expressions “at least one of A, B and C”, “at least one of A, B, or C”, “one or more of A, B, and C”, “one or more of A, B, or C” and “A, B, and/or C” means A alone, B alone, C alone, A and B together, A and C together, B and C together, or A, B and C together.

[0036] Unless otherwise indicated, all numbers expressing quantities, amounts, dimensions, conditions, and so forth used in the specification and claims are to be understood as being modified in all instances by the term “about”.

[0037] The term “a” or “an” entity, as used herein, refers to one or more of that entity. As such, the terms “a” (or “an”), “one or more” and “at least one” can be used interchangeably herein.

[0038] The use of “including,” “comprising,” or “having” and variations thereof herein is meant to encompass the items listed thereafter and equivalents thereof as well as additional items. Accordingly, the terms “including,” “comprising,” or “having” and variations thereof can be used interchangeably herein.

[0039] It shall be understood that the term “means” as used herein shall be given its broadest possible interpretation in accordance with 35 U.S.C. Section 112(f). Accordingly, a claim incorporating the term “means” shall cover all structures, materials, or acts set forth herein, and all of the equivalents thereof. Further, the structures, materials, or acts and the equivalents thereof shall include all those described in the summary of the invention, brief description of the drawings, detailed description, abstract, and claims themselves.

[0040] In varying embodiments described herein, the present invention relates to a compound that improves or enhances immune system functioning or that otherwise addresses immune deficiencies or disorders. Certain elements of the novel compounds and methods for formulating the same are described in varying levels of detail herein.

[0041] In embodiments, the composition is comprised of the foregoing elements:

Dried Yeast Fermentate

[0042] In a preferred embodiment, the composition comprises at least a Dried Yeast Fermentate (preferably derived from natural Saccharomyces cerevisiae), between about 250 mg to 750 mg. In a more embodiment, the composition comprises between about 400 and 600 mg of EpiCor® Yeast Fermentate. In a most preferred embodiment, the composition comprises about 500 mg of EpiCor® Yeast Fermentate (derived from natural Saccharomyces cerevisiae).

Olive Leaf Extract;

[0043] Olive Leaf Extract has been shown to have beneficial effect on the human immune system, particularly when taken in combination with the other components described herein.

[0044] In a preferred embodiment, the composition comprises Olive Leaf 20% Extract, preferably standardized to 20% Oleuropeins, between about 100 mg and about 300 mg. In a more preferred embodiment, the composition comprises between about 160 and 240 mg of Olive Leaf 20% Extract. In a most preferred embodiment, the composition comprises about 200 mg of Olive Leaf 20% Extract (standardized to 20% Oleuropeins).

Andrographis Extract

[0045] Andrographis Extract has also been found to improve immune system function. In a preferred embodiment, the composition comprises Andrographis Extract, preferably as standardized to 10% andrographolides, between about 100 mg and about 300 mg. In a more preferred embodiment, the composition comprises between about 160 and 240 mg of Andrographis Extract. In a most preferred embodiment, the composition comprises about 200 mg of Andrographis Extract (as standardized to 10% andrographolides).

N-acetylcysteine

[0046] In a preferred embodiment, the composition comprises N-acetylcysteine between about 100 mg and about 300 mg. In a more preferred embodiment, the composition comprises between about 160 and 240 mg of N-acetylcysteine. In a most preferred embodiment, the composition comprises about 200 mg of N-acetylcysteine.

Skullcap Root Extract

[0047] In a preferred embodiment, the composition comprises Skullcap Root Extract between about 50 mg and 150 mg. In a more preferred embodiment, the composition comprises between about 80 and 120 mg of Skullcap Root Extract. In a most preferred embodiment, the composition comprises about 100 mg of Skullcap Root Extract, preferably as Scutellaria Baicalensis Georgi (in root form) derived from 8-12:1 concentrate.

Trans-Resveratrol

[0048] Trans-Resveratrol has been found through experimentation to provide significant benefits to immune system functioning, particularly when provided in combination with the foregoing components. Resveratrol significantly reduces inflammatory cytokines that may reduce insulin and other natural productions of the human body. Further, Resveratrol has been found to assist in the balancing of healthy cholesterol ratios and reduce cardiovascular complications in human subjects.

[0049] Resveratrol is a powerful antioxidant, may reduce pain, fatigue and swelling, and may reduce the risk of cancer in human subjects. Resveratrol has also shown special benefits to individuals who also suffer from diabetes, are at risk of diabetes, or exhibit pre-diabetic symptoms.

[0050] Polygonum cuspidatum is the botanical name of Japanese knotweed, which in a preferred embodiment is provided as the form of the compound “Resveratrol.” This particular form assists with protection of ACE 2 receptors in the lungs, a known attachment site for Coronavirus and other viral infections, which enables rapid spreading.

[0051] In a preferred embodiment, the composition comprises between about 12.5 mg and 200 mg of Trans-Resveratrol, preferably from polygonum cuspidatum. In a more preferred embodiment, the composition comprises between about 15 and 50 mg of Trans-Resveratrol. In a most preferred embodiment, the composition comprises about 25 mg of Trans-Resveratrol (from polygonum cuspidatum).

Absent Elements

[0052] In addition, the composition of a preferred embodiment is substantially free of the following common allergens: milk, casein, gluten, wheat, eggs, peanuts, tree nuts, dairy, corn, soybeans, sugar and fish/shellfish. The composition preferably does not contain artificial colors, flavors, or preservatives, and is free from magnesium stearate (a common lubricant used in the manufacture of pharmaceuticals and dietary supplements).

Additional Elements

[0053] In varying embodiments, the composition can further comprise variances, particularly with respect to encapsulation and/or powder formulations. According to certain embodiments, the compositions described herein can further be provided with one or more palatability agents. These palatability agents serve to add flavor to the composition so that an effective dosage is easier to be ingested. It is within the scope of the present invention that any safe, flavor enhancing palatability agent can be used in a composition of the present invention. Particularly suitable palatability agents for use in the composition of the present invention include, but are not limited to, plant oils, plant hydrolysates, yeast, yeast hydrolysates, and combinations thereof.

Methods

[0054] An aspect of the invention is a method to treat a patient experiencing vision impairment, blurry vision, dry eyes, presbyopia, macular edema, cataracts, glaucoma, macular degeneration and temporal arteritis, among other conditions, with a composition comprising a unique combination and blend of Dried Yeast Fermentate (from natural Saccharomyces cerevisiae), Olive Leaf Extract (as standardized to 20% Oleuropeins), Andrographis Extract (as standardized to 10% andrographolides), N-acetylcysteine, Skullcap Extract (as Scutellaria Baicalensis Georgi derived from 8-12:1 concentrate), and Trans-Resveratrol (from polygonum cuspidatum), or combinations/sub-combinations thereof. According to one embodiment, during administration the patient is treated by providing an effective amount of the composition. In certain embodiments, the composition can be taken by the patient daily, with no regard to meals or time of day ingested. In a preferred embodiment, the composition is administered approximately 30 minutes prior to consumption of daily meals, or more than 2 hours following the patient's last meal. In one such embodiment, the composition is administered in the form of a capsule or two capsules that are fit for human consumption.

[0055] According to another embodiment, a method to prepare a compound is disclosed. The components are mixed in a proprietary blend and may be provided in a delivery device, for example, in the form of a capsule, tablet, lozenge or powder. The foregoing detailed description of the preferred embodiments is incorporated by reference in this portion of the specification.

[0056] While various embodiments of the present disclosure have been described in detail, it is apparent that modifications and alterations of those embodiments will occur to those skilled in the art. However, it is to be expressly understood that such modifications and alterations are within the scope and spirit of the present disclosure, as set forth in the following claims. Ranges have been discussed and used within the forgoing description. One of skill in the art will understand that any sub-range within the stated range would be suitable, as would any number within the broad range, without deviating from the spirit of the present invention.

[0057] The foregoing discussion of the disclosure has been presented for purposes of illustration and description. The foregoing is not intended to limit the disclosure to the form or forms disclosed herein. In the foregoing Detailed Description for example, various features of the disclosure are grouped together in one or more embodiments for the purpose of streamlining the disclosure. This method of disclosure is not to be interpreted as reflecting an intention that the claimed disclosure requires more features than are expressly recited in each claim. Rather, as the following claims reflect, inventive aspects lie in less than all features of a single foregoing disclosed embodiment.